EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Post‐authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi‐country European study

Niklas Schmedt iD, Ayman Alhamdow iD, Giorgi Tskhvarashvili iD, Laura Saarelainen iD, Xu Qiao iD, Muriel Lobier iD, Fabian Hoti iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16477 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Niklas Schmedt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim & Eli Lilly, Company Diabetes Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aimed to assess the risk of urinary tract cancers (UTCs), including bladder and renal cancers, in people with type 2 diabetes (T2D) initiating empagliflozin compared with people initiating any dipeptidyl peptidase‐4 inhibitor (DPP‐4i) in the United Kingdom (UK), Sweden, and Finland. Materials and Methods This was a non‐interventional, multi‐country cohort study based on secondary data in Sweden, Finland, and the UK. The study used an active comparator, new user design and included propensity score‐matched adults with T2D initiating empagliflozin or a DPP‐4i between 2014 and 2020 (2021 for the UK). Follow‐up started at the index date (first prescription or dispensation for empagliflozin or a DPP‐4i) and 180 days were considered as the latency period. Incidence rates (IRs) and hazard ratios (HRs) were estimated under an as‐treated approach in each country. HRs were then entered into a random‐effects meta‐analysis.

Results

The main analyses included 151 055 matched people. The mean age for empagliflozin initiators was 57.0–63.2 years across the countries, and most were female (59.6%–67.8%). A meta‐analysis of country‐level HR showed no evidence of an increased risk of UTC (adjusted HR = 0.88, 95% confidence intervals [CIs]: 0.66–1.17), bladder cancer (adjusted HR = 0.91, 95% CI: 0.63–1.33) or renal cancer (adjusted HR = 0.89, 95% CI: 0.57–1.38) for empagliflozin initiators compared with DPP‐4i initiators. Various sensitivity analyses also validated the robustness of the main findings.

Conclusions

No increased risk of UTC, bladder, and renal cancer was observed when empagliflozin initiators were compared with DPP‐4i initiators in this non‐interventional cohort study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsDiabetes Mellitus, Type 2GlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsUrologic NeoplasmsAgedFemaleHumansMaleMiddle AgedCohort StudiesDipeptidyl-Peptidase IV InhibitorsEuropeFinlandIncidenceRisk FactorsSwedenUnited Kingdom

Stichwörter der Autor:innen

CPRDDPP‐4 inhibitorSGLT2ibladder cancerdiabetes type 2epidemiologymeta‐analysisnordic countriesrenal cancerurinary tract cancer

Substanzen

Benzhydryl CompoundsDipeptidyl-Peptidase IV InhibitorsempagliflozinGlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • IQVIA, Tallinn, Estonia.
  • IQVIA, Espoo, Finland.

ORCID-Profile: Niklas Schmedt, Ayman Alhamdow, Giorgi Tskhvarashvili, Laura Saarelainen, Xu Qiao, Muriel Lobier, Fabian Hoti

Förderung

  • Boehringer Ingelheim & Eli Lilly
  • Company Diabetes Alliance

Zitieren

APA

Schmedt, N., Alhamdow, A., Tskhvarashvili, G., Saarelainen, L., Qiao, X., Lobier, M., & Hoti, F. (2025). Post‐authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi‐country European study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16477

Vancouver

Schmedt N, Alhamdow A, Tskhvarashvili G, Saarelainen L, Qiao X, Lobier M, et al. Post‐authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi‐country European study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16477

BibTeX
@article{Schmedt2025,
  author = {Schmedt, Niklas and Alhamdow, Ayman and Tskhvarashvili, Giorgi and Saarelainen, Laura and Qiao, Xu and Lobier, Muriel and Hoti, Fabian},
  title = {Post‐authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi‐country European study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16477}
}
Kostenlos starten →